



Comparison of Dosimetrical and Radiobiological Parameters on Three VMAT Techniques for Left-Sided Breast Cancer

Seong-Hee Kang¹, Jin-Beom Chung¹, Kyung-Hyeon Kim², Sang-Won Kang², Keun-Yong Eom¹, Changhoon Song¹, In-Ah Kim¹, Jae-Sung Kim¹

¹Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, ²Department of Biomedicine and Health Sciences, Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received 12 December 2018

Revised 27 December 2018

Accepted 17 January 2019

Corresponding author

Jin-Beom Chung

(jibchung1213@gmail.com)

Tel: 82-31-787-7654

Fax: 82-31-787-4019

Purpose: To compare the dosimetrical and radiobiological parameters among various volumetric modulated arc therapy (VMAT) techniques using restricted and continuous arc beams for left-sided breast cancer.

Materials and Methods: Ten patients with left-sided breast cancer without regional nodes were retrospectively selected and prescribed the dose of 42.6 Gy in 16 fractions on the planning target volume (PTV). For each patient, three plans were generated using the Eclipse™ system (Varian Medical System, Palo Alto, CA) with one partial arc 1pVMAT, two partial arcs 2pVMAT, and two tangential arcs 2tVMAT. All plans were calculated through anisotropic analytic algorithm and photon optimizer with 6 MV photon beam of VitalBEAM™. The same dose objectives for each plan were used to achieve a fair comparison during optimization.

Results: For PTV, dosimetrical parameters such as Homogeneity index, conformity index, and conformation number were superior in 2pVMAT than those in both techniques. $V_{95\%}$, which indicates PTV coverage, was 91.86%, 96.60%, and 96.65% for 1pVMAT, 2pVMAT, and 2tVMAT, respectively. In most organs at risk (OARs), 2pVMAT significantly reduced the delivered doses compared with the other techniques, excluding the doses to contralateral lung. For the analysis of radiobiological parameters, a significant difference in normal tissue complication probability was observed in ipsilateral lung while no difference was observed in the other OARs.

Conclusions: Our study showed that 2pVMAT had better plan quality and normal tissue sparing than 1pVMAT and 2tVMAT but not for all parameters. Therefore, 2pVMAT could be considered the priority choice for the treatment planning for left breast cancer.

Keywords: Left sided breast cancer, Volumetric modulated arc therapy, Dosimetrical parameters, Radiobiological parameters

Introduction

Adjuvant radiation therapy (RT) after breast conserving surgery which is the standard of care for early stage breast cancer has been mainly performed with 3D conformal

radiation therapy (3D CRT) using tangential fields.¹⁻³⁾ It is possible for the 3D CRT to provide adequate target coverage with relatively low complication rates.³⁾ However, normal tissue complications such as radiation pneumonitis and heart disease remain a concern.⁴⁻⁶⁾ There is mounting

evidence that even small delivered doses to the heart during RT are important in the long term survival.⁶⁾ In particular, left-sided breast cancer with concave shape is difficult to deliver the prescribed dose adequately without irradiation to portion of the lung and heart with 3D CRT.⁷⁾ During left sided breast RT, it is important to reduce the delivered dose to heart because patients could receive a relatively high cardiac dose which is associated with an increasing risk for heart complications.⁸⁾ In the study reported Darby et al.⁹⁾, the delivered heart dose to breast RT was increased the rate of major coronary events by 7.4% per Gy.

Dose inhomogeneity which is the predictor of radiation-induced toxicity can be increased by hot-spots within both target and surrounding normal tissues of large breast. Intensity-modulated radiation therapy (IMRT) which allows a homogeneous dose distribution to target has been used to mitigate normal tissue complication.^{10,11)} Xu et al.¹²⁾ reported that IMRT could significantly reduce heart dose in case of clinical target volume (CTV) more than 500 cc compared with conventional 3D CRT. However, several studies showed that IMRT using multiple fields increases the irradiated low-dose volumes in contralateral breast and both lungs.^{13,14)} In recent studies, volumetric modulated arc therapy (VMAT) technique has also been compared with various techniques such as 3D CRT and IMRT.^{14,15)} Badakhshi et al.¹⁶⁾ reported that the VMAT using two arcs was inferior to IMRT and 3D CRT for the dose distributions in organs at risk (OARs), especially for low doses and mean dose. However, doses to heart and ipsilateral lung could be reduced by VMAT using restricted tangential angles although the dose distribution on target was not improved.^{17,18)}

In this work, we compared various VMAT techniques using restricted arc beam and continuous arc beams to the left sided breast cancer to evaluate the delivered doses to OARs and dose homogeneity within the target volume. In addition, radiobiological parameters in lung and heart were analyzed to these techniques.

Materials and Methods

1. Patient selection and contouring

A total of ten patients with left-sided breast cancer without

regional nodes who underwent breast-conserving surgery for T0/T1 invasive ductal carcinoma were selected in this retrospective study. The mean age of the patients was 51 years (range, 41 to 70 years). CT simulation was performed with Brilliance CT Big Bore™ (Philips, USA) with 5-mm slice thickness. All patients were immobilized with the breast board (CIVICO Medical Solutions, USA) in a supine position. The images were transferred to treatment planning system (Eclipse, v. 13.7, Varian Medical System, USA). For each patient, the tumor bed was delineated as clinical target volume (CTV) which includes glandular breast tissue cropped 5 mm inside the body contour, and the planning target volume (PTV) was defined as the CTV plus a treatment margin of 10 mm for superior-inferior, 7 mm for anterior-posterior, and 5 mm for left-right to allow set-up uncertainties and account for respiratory motion. The breast PTVs ranged from 378 to 1,400 cc (775±300 cc). The OARs defined in heart, ipsilateral lung, and contralateral lung.

2. Dose prescription and objective

The dose of 42.6 Gy in 16 fractions was prescribed to the PTV as the Ontario Canadian trial.¹⁹⁾ The plan objectives are summarized in Table 1. The primary goal for planning was to cover at least 100% of the PTV with 95% of the prescribed dose to ensure dose coverage of target volume. For PTV homogeneity, 107% of prescribed dose was also limited to less than 1% of target volume. When the objectives of PTV were met, the objectives of OARs were determined in the following order of priorities: heart, left lung, contralateral lung.

3. Planning strategy

For each patient, the treatment plans were created by using the Eclipse™ system (Varian Medical System, USA)

Table 1. The optimization objectives used for inverse IMRT/VMAT planning.

Structure	Objectives
PTV	$V_{44.6\text{Gy}} < 1\%$, $V_{42.5\text{Gy}} > 95\%$, $V_{40.4\text{Gy}} > 100\%$
Heart	$V_{10\text{Gy}} < 20\%$ and $V_{20\text{Gy}} < 10\%$, $D_{\text{mean}} < 5\text{ Gy}$
Left lung	$V_{10\text{Gy}} < 40\%$, $V_{20\text{Gy}} < 30\%$ and $V_{30\text{Gy}} < 20\%$
Contralateral lung	$V_{10\text{Gy}} < 10\%$




Fig. 1. Example of dose distribution in transverse plane for (a) 1pVMAT, (b) 2pVMAT, and (c) 2tVMAT.

for three VMAT techniques as shown in Fig. 1: one partial arc VMAT (1pVMAT), two partial arcs VMAT (2pVMAT), and two tangential arcs VMAT (2tVMAT). Beam angle arrangements for each plan were slightly different according to PTV position and shape. Each beam was selected proper angles to meet the target coverage and avoid the collision with contralateral breast. First of all, 1pVMAT was generated using a single arc which ranges around 230° (range, 215° to 245°) to cover the entire treatment area. 2pVMAT was employed with two arcs which has the same arc range used in 1pVMAT. 2tVMAT was generated by using avoidance sector around 60° (range, 55° to 65°) under the same arc range used in 2pVMAT. The start and stop gantry angles of the avoidance sectors which were identified on a patient-by-patient based on their anatomy were manually set from 0° to 60°. All plans were used 6 MV photon beam of VitalBEAM™ with the Millennium 120™ MLC (Varian Medical System, USA). The same set of optimization goal for three type techniques was applied to accomplish fair comparison; hence, the observable discrepancies were mostly ascribed to the disparities of three VMAT techniques. In addition, the photon optimizer (PO, Ver. 13.7, Varian Medical Systems, USA) was used to optimize, and the dose distributions were calculated by the anisotropic analytic algorithm (AAA, Ver. 13.7, Varian Medical Systems, USA) with a calculation grid size of 2.5 mm.

4. Data analysis

In order to analyze the target coverage to PTV and doses to OARs, dose volume histograms (DVHs) for each plan was exported. For target coverage, dosimetric parameters

such as D_{\max} (max dose), D_{mean} (mean dose), and $V_{95\%}$ (percent volume irradiated by 95% of the prescription dose) of PTV were evaluated. Homogeneity index (HI), conformity index (CI), and conformation number (CN) of PTV were calculated to evaluate the plan quality. HI was calculated by Eq (1).

$$HI = \frac{D_{2\%} - D_{95\%}}{D_{50\%}} \dots (1)$$

Where, $D_{2\%}$, $D_{95\%}$ and $D_{50\%}$ indicate the dose to 2%, 95%, and 50% volume of the PTV, respectively. The lower HI was considered as a plan which has a more homogeneous target dose. The CI (as defined by the International Commission on Radiation Units and Measurements, report 83) is mathematically defined as:

$$CI = \frac{V_{RI}}{TV} \dots (2)$$

Where, V_{RI} is the volume of the target covered by the reference isodose, and TV is the volume of PTV. CI represents the objective measure of how well the distribution of radiation follows the shape of the target volume. The CI refers to the degree of dose conformity, and it is ideal for the CI to remain close to 1. The CN which evaluates the conformity to target dose and the healthy tissue irradiation was calculated as:

$$CN = \frac{TV_{RI}}{TV} \times \frac{TV_{RI}}{V_{RI}} \dots (3)$$

where TV_{RI} represents the target volume covered with reference isodose.

For OARs, D_{max} , D_{mean} , $V_{20\%}$, and $V_{10\%}$ (dose delivered to 20% and 10% volume) of contralateral lung, ipsilateral lung, and heart were evaluated. In order to investigate the radiobiological impact on various OARs, the equivalent uniform dose (EUD) based normal tissue complication probability (NTCP) were calculated using MATLAB software based program.²⁰⁾ The paired Wilcoxon' signed-rank test (SPSS, version 12; SPSS Inc, Chicago, IL) was performed for the statistical measure of the difference in dosimetrical parameters between various VMAT techniques. A P -value of <0.05 was considered to indicate statistical significance.

Results

1. Target coverage

Fig. 1 shows an example of dose distributions generated by (a) 1pVMAT, (b) 2pVMAT, and (c) 2tVMAT. Table 2 indicates the mean and standard deviation of dosimetrical parameters to PTV for all patients. Among three VMAT techniques, there were significant differences in dosimetrical parameters of PTV such as D_{max} , D_{mean} , $V_{95\%}$, HI, CI, and CN. The lowest D_{max} (114.93 ± 1.83) was observed in 2pVMAT, while D_{mean} (103.06 ± 1.65) was much higher than other techniques. Furthermore, the 2pVMAT ($V_{95\%} = 97.60 \pm 1.25$) technique provided significantly increased PTV dose coverage compared with both 1pVMAT ($V_{95\%} = 91.86 \pm 3.58$) and 2tV-

Table 2. Dosimetrical parameters to PTV obtained by three VMAT techniques (mean±standard deviation).

Metric	1pVMAT	2pVMAT	2tVMAT	P-value	
				1pVMAT vs. 2pVMAT	2pVMAT vs. 2tVMAT
D_{max} (%)	118.38±1.72	114.93±1.83	115.10±2.25	0.009	0.553
D_{mean} (%)	102.51±1.86	103.06±1.65	102.84±1.70	0.008	0.007
$V_{95\%}$ (%)	91.86±3.58	97.60±1.25	96.65±1.86	0.005	0.009
HI	0.21±0.04	0.12±0.02	0.14±0.03	0.005	0.007
CI	1.12±0.13	1.08±0.11	1.12±0.11	0.017	0.004
CN	0.76±0.05	0.88±0.06	0.83±0.05	0.005	0.005

Table 3. Dosimetrical and statistical analysis for the organs at risk according to three VMAT techniques (mean±standard deviation).

Organ	Metric	1pVMAT	2pVMAT	2tVMAT	P-value	
					1pVMAT vs. 2pVMAT	2pVMAT vs. 2tVMAT
Ipsilateral lung	D_{max} (%)	115.58±3.81	105.88±1.96	109.57±4.08	0.005	0.007
	D_{mean} (%)	32.60±3.21	28.67±1.71	30.27±2.84	0.005	0.011
	V_{20Gy} (%)	26.11±3.34	21.43±1.11	22.76±2.33	0.005	0.022
	V_{10Gy} (%)	43.13±6.59	37.49±3.76	39.75±4.95	0.005	0.017
	NTCP	0.04±0.03	0.01±0.01	0.02±0.01	0.011	0.038
Contralateral lung	D_{max} (%)	53.02±8.56	62.51±11.39	47.49±10.66	0.114	0.028
	D_{mean} (%)	6.81±1.65	10.29±6.94	6.94±1.13	0.005	0.007
	V_{20Gy} (%)	0.04±0.02	0.41±0.48	0.12±0.06	0.080	0.655
	V_{10Gy} (%)	1.70±1.29	4.91±3.23	1.38±1.23	0.009	0.022
	V_{5Gy} (%)	16.30±8.17	30.48±11.89	13.61±5.48	0.005	0.013
	NTCP	<0.001	<0.001	<0.001	-	-
Heart	D_{max} (%)	112.23±9.35	89.24±7.43	97.64±9.03	0.005	0.007
	D_{mean} (%)	17.79±4.03	14.66±1.82	15.98±3.83	0.012	0.185
	V_{20Gy} (%)	7.95±6.05	3.07±1.12	6.05±2.93	0.005	0.007
	V_{10Gy} (%)	19.77±7.02	15.21±4.05	16.60±8.51	0.012	0.445
	NTCP	<0.001	<0.001	<0.001	-	-

MAT ($V_{95\%}=96.65\pm 1.86$). The HI was 0.21 ± 0.04 , 0.12 ± 0.02 , and 0.14 ± 0.03 for 1pVMAT, 2pVMAT, and 2tVMAT, respectively. The doses were more conformal in the 2pVMAT compared to the 1pVMAT and 2tVMAT. The CI was lowest in the 2pVMAT ($CI=1.08\pm 0.11$), whereas it was similar for 1pVMAT ($CI=1.12\pm 0.13$) and 2tVMAT ($CI=1.12\pm 0.11$). The CN was higher in the 2pVMAT ($CN=0.88\pm 0.06$) than other two techniques.

2. Delivered doses to OARs

Table 3 indicates the dosimetrical parameters for delivered doses of OARs among the 1pVMAT, 2pVMAT, and 2tVMAT. The D_{max} (105.88 ± 1.96) and D_{mean} (28.67 ± 1.71) to ipsilateral lung in 2pVMAT were significantly lower than those in 1pVMAT and 2tVMAT. The D_{max} (62.51 ± 11.39) and D_{mean} (10.29 ± 6.94) of contralateral lung in 2pVMAT were also significantly lower than those in 1pVMAT and 2tVMAT. However, V_{20Gy} (21.43 ± 1.11) and V_{10Gy} (37.49 ± 3.76) of ipsilateral lung were significantly decreased in 2pVMAT, whereas V_{10Gy} (4.91 ± 3.23) and V_{5Gy} (30.48 ± 11.89) of contralateral lung was significantly increased in 2pVMAT compared with 1pVMAT and 2tVMAT. 2pVMAT was decreased significantly in D_{max} (89.24 ± 7.43) of heart compared with 1pVMAT (112.23 ± 9.35) and 2tVMAT (97.64 ± 9.03). However, there was no statistically significant difference in D_{mean} of heart with 2tVMAT (P -value=0.185). V_{20Gy} was significantly decreased in 2pVMAT (3.07 ± 1.12) compared with 1pVMAT (7.95 ± 6.05) and 2tVMAT (6.05 ± 2.93). However, no significant difference in V_{10Gy} with 2tVMAT (P -value=0.445) was observed. Only the average NTCP value of ipsilateral lung was observed to have a relatively apparent difference than those of the other OARs.

Discussion

In this study, we compared various VMAT techniques such as 1pVMAT, 2pVMAT, and 2tVMAT for left breast radiation therapy during the course of a hypo-fractionated RT comprising 16 fractions. Dosimetrical parameters of various techniques using 3D-CRT, IMRT, and VMAT in left breast cancer have been evaluated in a large of studies.^{7,12,15,16} These researches report that the IMRT or VMAT

for the dose homogeneity and coverage to target volume was significantly increased compared with 3D-CRT.¹³⁻¹⁶ In addition, VMAT was superior in both the treatment time and the number of MU compared with IMRT.²¹ Furthermore, VMAT had apparent advantage in reducing the volume of high dose to target volume and disadvantage in increasing the volume of lower dose.¹⁴⁻¹⁶ In this study, with respect to the dosimetrical parameters of PTV, 2pVMAT had obvious advantages on not only the HI but also CI and CN than other two techniques. The 2pVMAT was also improvement of the homogeneous dose distribution as shown in Fig. 1.

High doses to heart and left ascending coronary artery were decreased with the VMAT technique for left breast cancer. Especially, these are reasonable to consider the potential of VMAT techniques on breast cancer,¹⁴ because the mean dose and doses of 25 and 30 Gy to heart have been reported to be associated with the complication of heart.^{5,9} In the previous study, irradiation of the heart to delivered dose during breast radiotherapy resulted in an increase in the subsequent rate of ischemic heart disease linearly with the mean dose to the heart.⁹ Doses delivered to the heart (D_{max} , D_{mean} , V_{20Gy} , and V_{10Gy}) in 2pVMAT were the lowest in our study. This meant that the 2pVMAT could achieve the reduction of occurrence probability for the heart disease. The V_{20Gy} which could be used to predict the radiation pneumonitis risk was decreased in ipsilateral lung with 2pVMAT compared to other techniques. However, increasing the delivered dose to contralateral lung was concurrently observed in 2pVMAT. As expected, the low dose volume (V_{10Gy}) was significantly increased in 2pVMAT when comparing with 1pVMAT and 2tVMAT. Because the patients with breast cancer are considered long term survivors, the minimization of the delivered dose to contralateral lung is important. In our study, the V_{5Gy} and V_{10Gy} of contralateral lung for 2pVMAT were approximately 30% and 5%, although corresponding values for 2pVMAT were higher than two VMAT techniques. Because the dose constraints used in our study were excluded in V_{5Gy} of the contralateral lung, our study showed relatively high V_{5Gy} for all techniques compared with threshold presented in RTOG 1005 protocol.²² However, other dosimetrical results were in the same line with the previous studies.^{13,23} Fur-

thermore, these are also unclear that this low dose spreads are associated with clinical complication.

Even though the NTCP differences of OARs were only found in ipsilateral lung, the value is the smallest with 2pV-MAT. No remarkable difference of NTCP for other OARs was observed. This may be due to relatively simple target shape that does not include internal mammary node (IMN) and supra clavicle lymph (SCL).

A limitation of our study was to the small number of patient. It was difficult to provide the fully statistical significance for OARs. For example, we could not confirm the statistical significance of parameters such as D_{mean} and $V_{10\text{Gy}}$ to Heart (Table 2). Therefore, for future study, we need to investigate more complex shapes and various sizes of target volume for a large number of patients.

Conclusion

For three VMAT techniques of left breast cancer, the dosimetrical and radiobiological parameters were estimated in this study. This study founded that the plan quality was generally improved with 2pVMAT and, although not for all analyzed parameters, some dosimetrical parameters showed a significant improvement with 2pVMAT than with 1pVMAT and 2tVMAT. In addition, for radiobiological parameters, the 2pVMAT showed the significant improvement in NTCP of ipsilateral lung. Therefore, this study suggests that the use of 2pVMAT as choice for radiotherapy of left breast cancer may be an attractive option.

Acknowledgements

This work was supported by Grant No. 02-2014-028 from the Seoul National University Bundang Hospital (SNUBH) Research Fund and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2018R1D1A1B07049159).

Conflicts of Interest

The authors have nothing to disclose.

Availability of Data and Materials

All relevant data are within the paper and its Supporting Information files.

Ethics Approval and Consent to Participate

The study was approved by the institutional review board (IRB approval number; B-1902/520-106).

References

1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med* 2002; 347(16):1233-1241.
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med* 2002;347(16):1227-1232.
3. Munshi A, Pai RH, Phurailatpam R, et al. Do all patients of breast carcinoma need 3-dimensional CT-based planning? A dosimetric study comparing different breast sizes. *Med Dosim* 2009;34(2):140-144.
4. Pignol J, Olivetto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol* 2008;26(13):2085-2092.
5. Bird B, Swain S. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. *Clin Cancer Res* 2008;14(1):14-24.
6. Lohr F, El-Haddad M, Dobler B, et al. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. *Int J Radiat Oncol Biol Phys* 2009; 74(1):73-80.
7. Schubert LK, et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. *Radiother Oncol* 2010;100(2):241-246.
8. Nilsson G, Holmberg L, Garmo H, Duvernoy O, Sjögren I, Lagerqvist B, et al. Distribution of coronary artery stenosis after radiation for breast cancer. *J Clin Oncol* 2012;

- 30(4):380-386.
9. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013; 368(11):987-998.
 10. Hurkmans CW, Cho BCJ, Damen E, Zijp L, Mijnheer BJ. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. *Radiother Oncol* 2002; 62(2):163-171.
 11. Hong L, Hunt M, Chui C, Spirou S, Forster K, Lee H, et al. Intensity modulated tangential beam irradiation of the intact breast. *Int J Radiat Oncol Biol Phys* 1999;44(5):1155-1164.
 12. Xu XL, Wu H, Han SK. Dosimetry study of intensity modulated radiation therapy for left side breast cancer. *Chinese Journal of Radiation Oncology* 2006;15(3):192-195.
 13. Virén, Tuomas, et al. Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy. *Radiol Oncol* 2015;10(1):79.
 14. Jin, Guang-Hua, et al. A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different radiotherapy techniques: conventional tangential field, filed-in-filed, tangential-IMRT, multi-beam IMRT and VMAT. *Radiol Oncol* 2013;8(1):89.
 15. Qiu, Jian-Jian, et al. Dosimetric comparison of 3D conformal, IMRT, and V-MAT techniques for accelerated partial-breast irradiation (APBI). *Med Dosim* 2014;39(2):152-158.
 16. Badakhshi H, Kaul D, Nadobny J, Wille B, Sehoul J, Budach V. Image-guided volumetric modulated arc therapy for breast cancer: a feasibility study and plan comparison with three-dimensional conformal and intensity-modulated radiotherapy. *Br J Radiol* 2013;86(1032):20130515.
 17. Munshi, Anusheel, et al. Short tangential arcs in VMAT based breast and chest wall radiotherapy lead to conformity of the breast dose with lesser cardiac and lung doses: a prospective study of breast conservation and mastectomy patients. *Australas Phys Eng Sci Med*. 2017;40(3): 729-736.
 18. Fogliata, Antonella, et al. Dosimetric trade-offs in breast treatment with VMAT technique. *Br J Radiol* 2016;90(1070): 20160701.
 19. Whelan, Timothy J, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med* 2010;362(6):513-520.
 20. Gay HA, Niemierko A. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. *Phys Med* 2007;23:115-125.
 21. Liu, Haiyun, et al. Evaluation of 3D-CRT, IMRT and VMAT radiotherapy plans for left breast cancer based on clinical dosimetric study. *Comput Med Imaging Graph* 2016;54: 1-5.
 22. Vicini, F., G. M. Freedman, and J. R. White. A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. *RTOG 1005*. 2012.
 23. Xi, Dan, et al. Advantages of a technique using two 50 degree arcs in simultaneous integrated boost radiotherapy for left-sidebreast cancer. *Sci Rep* 2017;7(1):14748.